Large-scale studies examining the demographic, serologic, and seasonal characteristics of myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) and aquaporin-4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) remain limited, despite their potential to provide crucial information for resource allocation, clinical trial design, and recruitment. The goals of this study were to investigate demographic, serologic, and seasonal variations in MOGAD and AQP4+NMOSD using a large neuroimmunology laboratory registry validated by clinical cohorts.
Vorasoot et al. (Mon,) studied this question.